{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:07:24Z","timestamp":1792098444003,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s10637-018-0707-5","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T02:56:25Z","timestamp":1544151385000},"page":"567-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Seop","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"707_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020\u20131022. https:\/\/doi.org\/10.1002\/hep.24199","journal-title":"Hepatology"},{"key":"707_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"707_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"707_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch\u00fctz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245\u2013255. https:\/\/doi.org\/10.1002\/ijc.25864","journal-title":"Int J Cancer"},{"key":"707_CR5","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","volume":"12","author":"L Abou-Elkacem","year":"2013","unstructured":"Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, Lederle W (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12:1322\u20131331. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1162","journal-title":"Mol Cancer Ther"},{"key":"707_CR6","doi-asserted-by":"publisher","first-page":"107096","DOI":"10.18632\/oncotarget.22334","volume":"8","author":"M Kissel","year":"2017","unstructured":"Kissel M, Berndt S, Fiebig L, Kling S, Ji Q, Gu Q, Lang T, Hafner FT, Teufel M, Zopf D (2017) Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 8:107096\u2013107108. https:\/\/doi.org\/10.18632\/oncotarget.22334","journal-title":"Oncotarget"},{"key":"707_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"707_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng A-L, el-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen YH, Park JW, Blanc JF, Bolondi L, Kl\u00fcmpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"key":"707_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"707_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M, Alistar A, Asselah J, Blanc JF, Borbath I, Cannon T, Chung K, Cohn A, Cosgrove DP, Damjanov N, Gupta M, Karino Y, Karwal M, Kaubisch A, Kelley R, van Laethem JL, Larson T, Lee J, Li D, Manhas A, Manji GA, Numata K, Parsons B, Paulson AS, Pinto C, Ramirez R, Ratnam S, Rizell M, Rosmorduc O, Sada Y, Sasaki Y, Stal PI, Strasser S, Trojan J, Vaccaro G, van Vlierberghe H, Weiss A, Weiss KH, Yamashita T (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"},{"key":"707_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/liv.13096","volume":"36","author":"M Kudo","year":"2016","unstructured":"Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladr\u00f3n de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL (2016) Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 36:1196\u20131205. https:\/\/doi.org\/10.1111\/liv.13096","journal-title":"Liver Int"},{"key":"707_CR12","doi-asserted-by":"publisher","unstructured":"Kudo M, Meinhardt G, Bruix J (2017) Regorafenib as second-line treatment of patients with hepatocellular carcinoma (HCC) who progressed on Sorafenib: subgroup analysis of patients from Asia in the phase 3 RESORCE trial. Liver Cancer 6:S8\u20131. https:\/\/doi.org\/10.1159\/000478029","DOI":"10.1159\/000478029"},{"key":"707_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jjco\/hyq073","volume":"40","author":"C Yoo","year":"2010","unstructured":"Yoo C, Kim JE, Lee J-L, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H (2010) The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40:980\u2013985. https:\/\/doi.org\/10.1093\/jjco\/hyq073","journal-title":"Jpn J Clin Oncol"},{"key":"707_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","volume":"69","author":"RS Finn","year":"2018","unstructured":"Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J (2018) Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol 69:353\u2013358. https:\/\/doi.org\/10.1016\/j.jhep.2018.04.010","journal-title":"J Hepatol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0707-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:09Z","timestamp":1678559529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0707-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yoo C, honorarium from Bayer.Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was acquired from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}